Busan, South Korea

Jae-Seon Kang

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 7.5

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Jae-Seon Kang in Anti-Inflammatory and Anti-Angiogenic Research

Introduction

Jae-Seon Kang is a notable inventor based in Busan, South Korea. He has made significant contributions to the field of pharmaceutical compositions, particularly focusing on anti-inflammatory and anti-angiogenic agents. With a total of 2 patents to his name, his work has the potential to impact various medical applications.

Latest Patents

Kang's latest patents include an anti-inflammatory composition containing macrolactin A and its derivatives. This invention highlights the anti-inflammatory properties of macrolactin compounds, which are derived from a novel strain of KJS-2 (KCCM10769P). The compounds have been shown to effectively suppress the expression of inducible nitric oxide synthetase (iNOS) and cyclooxygenase-2 (COX-2), which are crucial in the inflammatory response. Additionally, these compounds inhibit the formation of nitric oxide (NO) and prostaglandin E2 (PGE2), thereby providing excellent anti-inflammatory agents.

Another significant patent by Kang is an anti-angiogenic composition that also utilizes macrolactin A and its derivatives. This composition has demonstrated strong suppression of angiogenesis in in vivo experiments, indicating its potential as a pharmaceutical treatment for diseases associated with abnormal blood vessel formation.

Career Highlights

Jae-Seon Kang is currently associated with Daewoo Pharmaceutical Ind. Co., Ltd., where he continues to innovate in the field of pharmaceuticals. His research focuses on developing effective treatments that leverage the unique properties of macrolactin compounds.

Collaborations

Kang has collaborated with notable colleagues such as Young-Hoon Ji and Dong-Hee Kim. Their combined expertise has contributed to the advancement of research in anti-inflammatory and anti-angiogenic therapies.

Conclusion

Jae-Seon Kang's innovative work in the development of macrolactin-based pharmaceutical compositions showcases his commitment to addressing significant health challenges. His contributions have the potential to lead to new treatments for inflammatory and angiogenesis-related diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…